On Friday, August 07, Meridian Bioscience VIVO will release its latest earnings report. Check out Benzinga's preview to understand the implications.
Earnings and Revenue
Based on Meridian Bioscience management projections, analysts predict EPS of $0.25 on revenue of $66.04 million. In the same quarter last year, Meridian Bioscience announced EPS of $0.16 on revenue of $48.44 million. If the company were to post earnings in-line with the consensus estimate when it reports Friday, EPS would be up 56.25%. Here's how the company's reported EPS has compared to analyst estimates in the past:
Quarter | Q2 2020 | Q1 2020 | Q4 2019 | Q3 2019 |
---|---|---|---|---|
EPS Estimate | 0.08 | 0.07 | 0.09 | 0.09 |
EPS Actual | 0.23 | 0.10 | 0.13 | 0.16 |
Revenue Estimate | 49.26 M | 48.90 M | 50.59 M | 49.81 M |
Revenue Actual | 57.30 M | 47.42 M | 50.85 M | 48.44 M |
Stock Performance
Over the last 52-week period, shares are up 117.93%. Given that these returns are generally positive, long-term shareholders should be content going into this earnings release.
Don't be surprised to see the stock move on comments made during its conference call. Meridian Bioscience is scheduled to hold the call at 10:00:00 ET and can be accessed here: https://investor.meridianbioscience.com/events/event-details/q3-2020-financial-results-conference-call
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.